AR126579A1 - ANTIGEN-BINDING PROTEINS THAT BIND SPECIFICALLY TO CT45 - Google Patents
ANTIGEN-BINDING PROTEINS THAT BIND SPECIFICALLY TO CT45Info
- Publication number
- AR126579A1 AR126579A1 ARP220101987A ARP220101987A AR126579A1 AR 126579 A1 AR126579 A1 AR 126579A1 AR P220101987 A ARP220101987 A AR P220101987A AR P220101987 A ARP220101987 A AR P220101987A AR 126579 A1 AR126579 A1 AR 126579A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- binding proteins
- binding protein
- polypeptide
- protein
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title abstract 8
- 108091000831 antigen binding proteins Proteins 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona a una proteína de unión a antígenos que se une específicamente a un péptido antigénico de CT45 que está formando un complejo con una proteína del complejo principal de histocompatibilidad (MHC), péptido antigénico de CT45 que comprende o consiste en la secuencia de aminoácidos de la SEQ ID Nº 138 (KIFEMLEGV) y en que la proteína de unión a antígenos comprende un primer polipéptido que comprende un dominio variable VA el cual comprende las regiones determinantes de la complementariedad CDRa1, CDRa2 y CDRa3 y un segundo polipéptido que comprende un dominio variable VB que comprende las CDRb1, CDRb2 y CDRb3. Además, se proporcionan ácidos nucleicos que codifican las proteínas de unión a antígenos de la invención, vectores que comprenden esos ácidos nucleicos, células recombinantes que expresan las proteínas de unión a antígenos y composiciones farmacéuticas que comprenden las proteínas de unión a antígenos. La invención proporciona, además, las proteínas de unión a antígenos para el uso en medicina y un método para producir la proteína de unión a antígenos.The present invention provides an antigen-binding protein that specifically binds to a CT45 antigenic peptide that is complexed with a major histocompatibility complex (MHC) protein, CT45 antigenic peptide comprising or consisting of the sequence of amino acids of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a VA variable domain which comprises the complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a VB variable domain comprising CDRb1, CDRb2 and CDRb3. Additionally, provided are nucleic acids encoding the antigen-binding proteins of the invention, vectors comprising those nucleic acids, recombinant cells expressing the antigen-binding proteins, and pharmaceutical compositions comprising the antigen-binding proteins. The invention further provides antigen binding proteins for use in medicine and a method for producing the antigen binding protein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063335399P | 2020-04-27 | 2020-04-27 | |
| US202063203582P | 2020-07-27 | 2020-07-27 | |
| EP21188018 | 2021-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126579A1 true AR126579A1 (en) | 2023-10-25 |
Family
ID=88679234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101987A AR126579A1 (en) | 2020-04-27 | 2022-07-27 | ANTIGEN-BINDING PROTEINS THAT BIND SPECIFICALLY TO CT45 |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126579A1 (en) |
-
2022
- 2022-07-27 AR ARP220101987A patent/AR126579A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120585A1 (en) | ANTIGEN-BINDING PROTEINS THAT BIND SPECIFICALLY TO MAGE-A | |
| PE20191463A1 (en) | BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3 | |
| AR121587A2 (en) | NEW PEPTIDES AND A NEW PEPTIDE COMBINATION FOR USE IN IMMUNOTHERAPY AGAINST PANCREATIC CANCER AND OTHER TYPES OF CANCER | |
| UY36536A (en) | ANTI-CD3 ANTIBODIES, ANTI-CD123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123 | |
| DOP2019000011A (en) | BISPECIFIC ANTIBODY TYPE UNION PROTEINS THAT SPECIFICALLY JOIN CD3 AND CD123 | |
| PE20050712A1 (en) | RG1 ANTIBODIES | |
| HUP0004639A2 (en) | Chlamydia protein, gene sequence and uses thereof | |
| MX2022000652A (en) | Claudin18 antibodies and methods of treating cancer. | |
| AR109450A1 (en) | ILT7 BINDING MOLECULES AND SAME USE METHODS | |
| MX2021010281A (en) | Antigen binding proteins that bind bcma. | |
| AR126579A1 (en) | ANTIGEN-BINDING PROTEINS THAT BIND SPECIFICALLY TO CT45 | |
| CO2024000677A2 (en) | Antigen-binding proteins that specifically bind to ct45 | |
| CN101103108B (en) | HLA-binding peptides, DNA fragments encoding the same and recombinant vectors | |
| CL2009001284A1 (en) | Antibodies or antigen-binding fragments thereof that bind il-21r; pharmaceutical composition comprising it; coding nucleic acids; expression vectors and isolated host cells; diagnostic kit comprising said antibodies | |
| EA201991444A1 (en) | NEW PEPTIDES AND PEPTID COMBINATIONS FOR APPLICATION IN THE IMMUNOTHERAPY OF OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| AR127176A1 (en) | ANTIGEN-BINDING POLYPEPTIDES, ANTIGEN-BINDING POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | |
| ATE509025T1 (en) | ßMEMBRANE-ANCHORED BETA2-MICROGLOBULINß COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES | |
| JPWO2020071554A5 (en) | ||
| BR112023022765A2 (en) | ANTIGEN-BINDING PROTEINS THAT SPECIFICALLY BIND PRAME | |
| ES2664725T3 (en) | Methods and materials for generating CD8 + T cells with the ability to recognize cancer cells that express an HER2 / neu polypeptide | |
| MX2023007583A (en) | Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same. | |
| AR100427A1 (en) | PROTEINS OF UNION TO ANTIGEN OF HER1 THAT JOIN THE FORK b OF HER1 | |
| Hay et al. | Cattle killer immunoglobulin-like receptor expression on leukocyte subsets suggests functional divergence compared to humans | |
| AR125763A1 (en) | ANTIGEN-BINDING PROTEINS THAT SPECIFICALLY BIND PRAME | |
| BR112023025884A2 (en) | NKG2D ANTIBODY LIGAND DOMAIN FUSION PROTEIN |